Alkermes plc (NASDAQ: ALKS) announced today that it will webcast its Analyst and Investor Event presentation on Monday, September 26, 2016. The webcast will begin at 2:00 p.m. EDT (7:00 p.m. BST). At the event, members of Alkermes’ senior management will provide an overview of medical, commercial, policy and market perspectives for VIVITROL® (naltrexone for extended-release injectable suspension).
A live webcast of the event will be available on the Investors section of the company’s website at www.alkermes.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start. This webcast will be archived on the Investors section of the company’s website at www.alkermes.com for one month following the presentation.
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160919006058/en/Business Wire
Last updated on: 19/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.